Skip to content

Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal

Implementing and Evaluating an Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07717619
Enrollment
100
Registered
2026-07-21
Start date
2026-08-01
Completion date
2028-07-31
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Risk Pregnancy

Keywords

high risk pregnancy, low and middle income countries, teleheatlh, pregnancy checklist

Brief summary

The proposed study will assess and implement a comprehensive antenatal HRP screening and telehealth follow-up program in rural Nepal. The main questions it aims to answer are: 1. To estimate the burden of HRPs using the existing Antenatal Risk-Score Checklist in rural Nepal 2. Assess acceptability, feasibility, preliminary effectiveness, and implementation outcomes of the HRP bundle at the primary healthcare in Nepal

Interventions

OTHERHigh Risk Pregnancy Bundle

The intervention would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
0 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* all pregnant women above who are receiving antenatal care at Melamchi Primary Health Care Center

Exclusion criteria

* life-threatening maternal or fetal conditions requiring immediate tertiary-level care * unable to provide informed consent due to cognitive or language barriers * do not have access to a mobile phone for telehealth consultations.

Design outcomes

Primary

MeasureTime frameDescription
Maternal Near Missup to 60 days postpartumlife-threatening complication during pregnancy, childbirth, or within 42 days postpartum, but survives with appropriate medical intervention (We will use WHO criteria)

Secondary

MeasureTime frameDescription
Neonatal deathUp to 28 days after birthNumber of neonatal deaths, defined as death of a liveborn infant within the first 28 days of life
Low Apgar Score at 5 MinutesAt 5 minutes after birthNumber of infants with an Apgar score less than 7 at 5 minutes after birth
Neonatal Intensive Care Unit AdmissionUp to 30 days after birthNumber of infants admitted to a neonatal intensive care unit
Need for Mechanical Ventilationup to 30 days after birthNumber of infants requiring mechanical ventilation
Neonatal Respiratory Distress SyndromeUp to 30 days after birthNumber of infants diagnosed with respiratory distress syndrome
Neonatal HypoglycemiaUp to 48 hours after birthNumber of infants with hypoglycemia, defined as less than 45 mg/dl
Low Birth WeightAt birthNumber of infants with birth weight less than 2500 grams
Composite Adverse Neonatal Outcomeup to 30 days after birthNumber of infants with at least one of the following: neonatal death, Apgar score less than 7 at 5 minutes, NICU admission, need for mechanical ventilation, respiratory distress syndrome, hypoglycemia
Antenatal Risk Screening RateUp to 24 monthsProportion of pregnant women enrolled in the study who undergo antenatal risk screening using the Antenatal Risk-Score Checklist
Referral RateUp to 24 monthsPercentage of pregnant women referred to higher levels of care based on risks identified through antenatal risk screening
Telehealth Consultation Utilization RateUp to 24 monthsProportion of pregnant women in the High Risk Pregnancy Bundle Intervention Arm who utilize at least 80% of their recommended telehealth consultations

Countries

Nepal

Contacts

CONTACTAnju Ranjit, MD MPH
anju.ranjit@ucsf.edu4153533400
CONTACTArchana Shrestha, PhD
archana@kusms.edu.np+9779801002245
PRINCIPAL_INVESTIGATORAnju Ranjit, MD MPH

University of California, San Francisco

PRINCIPAL_INVESTIGATORArchana Shrestha

Kathmandu University School of Medicine/Dhulikhel Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026